0001683168-24-001606.txt : 20240322 0001683168-24-001606.hdr.sgml : 20240322 20240322080003 ACCESSION NUMBER: 0001683168-24-001606 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240322 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240322 DATE AS OF CHANGE: 20240322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenetic Biosciences, Inc. CENTRAL INDEX KEY: 0001534525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452952962 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37937 FILM NUMBER: 24773120 BUSINESS ADDRESS: STREET 1: 945 CONCORD ST. CITY: FRAMINGHAM STATE: MA ZIP: 01701 BUSINESS PHONE: 781-778-7720 MAIL ADDRESS: STREET 1: 945 CONCORD ST. CITY: FRAMINGHAM STATE: MA ZIP: 01701 FORMER COMPANY: FORMER CONFORMED NAME: General Sales & Leasing, Inc. DATE OF NAME CHANGE: 20130227 FORMER COMPANY: FORMER CONFORMED NAME: GENERAL AIRCRAFT INC. DATE OF NAME CHANGE: 20111108 8-K 1 xenetic_8k.htm CURRENT REPORT
false 0001534525 0001534525 2024-03-22 2024-03-22 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2024-03-22 2024-03-22 0001534525 XBIO:PurchaseWarrantsMember 2024-03-22 2024-03-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

 

FORM 8-K

________________________

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 22, 2024

________________________

 

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in charter)

 

Nevada   001-37937   45-2952962
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

945 Concord Street  
Framingham, Massachusetts 01701
(Address of principal executive offices) (Zip Code)

 

(781) 778-7720

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value per share   XBIO   The Nasdaq Stock Market
Purchase Warrants   XBIOW   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On March 22, 2024, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the year ended December 31, 2023 and providing a corporate update.

 

The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

FORWARD-LOOKING STATEMENTS

 

This Form 8-K, including the press release, contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K, including the press release, other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements or results to differ materially from the activities and results anticipated in forward-looking statements. These risks and uncertainties include those described in the “Risk Factors” section as detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission (“SEC”), including the Company’s annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak and, geopolitical events, such as the Russian invasion of Ukraine and conflict in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this Form 8-K, including the press release, speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release dated March 22, 2024 pertaining to the financial results of the Company for the year ended December 31, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

 2 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  XENETIC BIOSCIENCES, INC.
   
  By: /s/ James Parslow                                        
Date: March 22, 2024 Name:   James Parslow
  Title:     Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
 EX-99.1 2 xenetic_ex9901.htm PRESS RELEASE

Exhibit 99.1

 

 

 

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

 

Continued advancement of DNase-based oncology program towards Phase 1

clinical study for the treatment of pancreatic carcinoma and other locally

advanced or metastatic solid tumors

 

Ended the year with $9.0 million of cash to fund operations

 

FRAMINGHAM, MA – (March 22, 2024) – Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the year ended December 31, 2023.

 

Recent Highlights

 

·Entered into a Research Funding Agreement and a Material Transfer Agreement with the University of Virginia ("UVA") to advance the development of the DNase program.
·Generated growing body of encouraging preclinical data guiding the approach to a first in human trial for systemic DNase-based oncology platform.

 

"We continued to make steady progress over the course of 2023 and are well positioned to continue on that pathway in 2024. With the encouraging preclinical data we continue to see with our DNase-based oncology platform, we are making noteworthy strides toward our first in human trial. We believe that our DNase platform, comprising multiple treatment modalities, has the potential to generate much needed therapies for pancreatic carcinoma and other locally advanced or metastatic solid tumors, and we are excited to unlock the full potential of our assets," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

 

Summary of Financial Results for Fiscal Year 2023

 

Net loss for the year ended December 31, 2023 was approximately $4.1 million. Research and development expenses for the year ended December 31, 2023 decreased by $1.3 million, or 26.7%, to $3.5 million from $4.8 million in the prior year period. This decrease was primarily due to in-process research and development expense of $1.8 million in 2022 associated with our licensing of the DNase platform for which there was no similar expense in 2023. Royalty payments of approximately $2.5 million were received from our sublicense with Takeda Pharmaceuticals Co. Ltd in the year ended December 31, 2023, representing an approximate 48.8% increase over the same period in 2022. General and administrative expenses for the year ended December 31, 2023 were $3.6 million, decreasing by approximately $0.1 million, or 2.5%, compared to the prior year. The decrease was primarily due to a decrease in employee related costs, substantially offset by increases in consulting and legal costs during the year ended December 31, 2023 compared to the prior year.

 

The Company ended the year with approximately $9.0 million of cash.

 

About Xenetic Biosciences

 

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

 

For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

 

 

 1 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding: all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors, our belief that we are well positioned to continue on a similar pathway in 2024, encouraging preclinical data and making noteworthy strides toward our first in human trial, our belief that our DNase platform, comprising multiple treatment modalities, has the potential to generate much needed therapies for pancreatic carcinoma and other locally advanced or metastatic solid tumors, our excitement to unlock the full potential of our assets, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the Russian invasion of Ukraine and conflict in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

 

Contact:

 

JTC Team, LLC

Jenene Thomas

(833) 475-8247

xbio@jtcir.com

 

 

 

 

 

 2 

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 xbio-20240322.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 xbio-20240322_def.xml XBRL DEFINITION FILE EX-101.LAB 6 xbio-20240322_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, $0.001 par value per share Purchase Warrants Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 xbio-20240322_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 22, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 22, 2024
Entity File Number 001-37937
Entity Registrant Name Xenetic Biosciences, Inc.
Entity Central Index Key 0001534525
Entity Tax Identification Number 45-2952962
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 945 Concord Street
Entity Address, City or Town Framingham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 01701
City Area Code (781)
Local Phone Number 778-7720
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock, $0.001 par value per share  
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol XBIO
Security Exchange Name NASDAQ
Purchase Warrants  
Title of 12(b) Security Purchase Warrants
Trading Symbol XBIOW
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 3 22 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://xeneticbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports xbio-20240322.xsd xbio-20240322_def.xml xbio-20240322_lab.xml xbio-20240322_pre.xml xenetic_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xenetic_8k.htm": { "nsprefix": "XBIO", "nsuri": "http://xeneticbio.com/20240322", "dts": { "schema": { "local": [ "xbio-20240322.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "xbio-20240322_def.xml" ] }, "labelLink": { "local": [ "xbio-20240322_lab.xml" ] }, "presentationLink": { "local": [ "xbio-20240322_pre.xml" ] }, "inline": { "local": [ "xenetic_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 25 }, "report": { "R1": { "role": "http://xeneticbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xenetic_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "xenetic_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://xeneticbio.com/role/Cover" ], "auth_ref": [] }, "XBIO_CommonStock0.001ParValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240322", "localname": "CommonStock0.001ParValuePerShareMember", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, $0.001 par value per share" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "XBIO_PurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://xeneticbio.com/20240322", "localname": "PurchaseWarrantsMember", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Purchase Warrants" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://xeneticbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001683168-24-001606-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-001606-xbrl.zip M4$L#!!0 ( ! =E@HU6WXQ0, *\. 1 >&)I;RTR,#(T,#,R,BYX M,T4N99+&S#!0%)Y:Y,SQ?4IL^P"[7YF(I/K2[R[L3HQ)=^3N,?L]UN"#_=2M3^6;>Y\,Q$^?9AV"8WC]0 M>G-+>^;I[,Q__=_C?)KTO5$_N9T^S;*;YOFG,7\3?.2)?S[\<%FX;.MPPA)* MX#"$[EB87YG>K.E(-79]SVNXP_N[08ZS"F!K'G/QN W>N+BX<'-M!:TAYX&* M*]--%]4!U6QA&;1\#YX+;:@(U_"161!6P6=NH5R#\JW0UP645]"(;> T"YVQ MG+J@ +S?K("9ML>4I@OPB.H@-UHJUL!:F3H0A)L@VSRE3&^%%JHU0F34!F%M MUT#MHAHYONTU[6:C8@[_[3XLTX1+9'@8<(GUC.B_O:;OPZV,6<*$N98JN6(C MFL60Q(^,QGS$66010]68&2Q0G=*0/6NOJG,JA(3K '>RE* L33G4^T( (JR/ MEI(Q^PPY$%S ?=SE!-7NI82N8A$>=:QBN6*N,ABQ$1<\=U[>P :Q\;YEF"HL MK$_T.:3M04!4$/>RYP/D9;>Y4 MZ;@R0558LU)K,&!$IDP9#O=AI8L4H7.#]-Z*&X)^M$7<7YAY3(-C,P<*BU\P MY3NT_Q*Y0I4=F^MZ8;Y0PE<+)_6LV^YZ1X'OS:[3AL2E,D34&MB^MZ=X->]D MF)O:0\$ON^+9*+(;/K1@9ZZC9:3'!+''L/KN_D0,N9FC@GC^,=\5SG/,_%N?5 2AS(113\<4 MPBJE^CCM-)83TV$'4>&+0\ AZE2W)U1!W?G.$B@'K7QRP='L._Q[2:08&!D^ M>@Z,*#VJ\N&_Q]1@0A6[9TF HPX&CPR.$K=.H#+LI3MPMZ+)<1I_S MQR#*5)X3#'?%=S5AMB*94"ZZAB6(A#W( @U].$/TC9)9BJ\&FN, V9=:+U/A M!+K1-ZH4%4:OI[)3^WM#;[O%&#:93CN>5(@%B'*& MSSN,=W[YS]__YNF?3S]UN]X5P30X\SYSOSME"_ZS]PVM\9GW*V98(,7%S]YW M1$.SA5\1BH4WX>M'BA76.^*&S[S3D^$0>=UNC7J_8Q9P\=;K M/3\_GS#^A)ZY>) G/E_7JW"FD KEKK;^II_\Q,4_4<(>SLRO.9+8TWHQ>;:1 MY+QCVDV:?1Z=<+'L#?O]0>_/KU]F_@JO49S34JN!)X<=[9:("N?_BA/QH.3>W_R('4]E'W8DE,)^QXO5S+2/AIXS9P MMA4@SE1N$^!IU/A*5R'\<(Z[ 5EC9CI\QTL:RD67UD*8ZFEH+\'TK!6\/>]= M8]V KQ$YDG2QM /&44O=-5[/C=U'TL-Q-&S%#W17_-\<8;I<\\.$B9FPKKCTR** -/SBP#KVM. M0Z%FH_3'&)D02:E0[N?:IV8,YJ(HG$PC7B YC\(.97>)T*.6<#CJ8:IDNL6, MBJ-(R&3#O3GY84-#QXNG^J-,&Z!HCFG4['T"MF%[[\OZ#LWW?:F$<8([9+NW M>RQ2WDE?J7E QAWTS.=,Z0YR2:/6="?'2_,A9;80?%TI92(;+XT@JZTFTO&X M"+#0,[?^G@OE$@?G'25"2\B.#9I0).7U8J:X_S#>D#J]JUCD56VSGDVK;,JK M#U@$Q6IQZ[U\R5+\G)R7(4-LV%=UHCA%J+(!5)A7,H>L&/;;Z<7]P$+\M>Q( M3XY_=71[L5]1=)!EHY=:5DP,_KR87M_K?'3-6=1Z_T2?G&^0B'+!&RQF*R3P MUV126##'E*Y7^ WVE0QK@R4TH_)7.$W\@(1!3LM0# M._C>=F@W1O,2SN!0]2JG#8G]DR5_Z@68Q*.4_K ?G/27^W1F>J=KM"BN(5G$ M_8?WD;EZ"F4C"FG[*F>!:FG'FDQ@"%U1M+1KFX,T6MPBTS>=[QRA[F M569N!XB<0;9#ZT/"X&#A=JRXQ4LBE8BN$NX"*A\\K$4:;4(U /,4?X+L1L>9\&PE18,RRUPE/]"[$;' M63!JI06C<@L<9<$Y=A/]\5K<\6?@[CL ;H_\!YQ!\9VFP FW*)IK<2/X$XD? MXZERX*!$>VRP$0>]<)HFI_TDGB[4.0IB9'NTSQ(&-7>:)B?$;KA4B/Z//%;- M3FWX]NA?I VZX"AK3GJ$N8P"+;O*01JM=9$I**^CU-B<<\8"([A;9Q'-%O>0 M**BMHSSW"S=W=5:89.@L/#;G>CE41'7 M:,$!NJ#:CK++&X%-'\!ZDA\MAC,/XHKKQ0(:J6%\H]6OH VZX"C-/* WE3+$ MXE@O"J7:Y(B=/.B+HY1SAOU0#Y3;P7!^9QXS!T:B U2C=;>2!75VE&9^XW<" MF3?CS+;K.:?P(SP68*/5AOB"@CO**'.L[%+G((T6N<@4E-=11ID>9)<;?X78 M$L,K.FS(1HL-$@8U=Y1I[@>V9:VQ>MFFL7I98ZQVE&FFI.*%^OJXNYY3LD3P M$X$E!5JA/L0;,L(6TUL8$3^O9=ZW)M81JRO]P6Z!%=IH\6'&H.RN'H4- Z)P M$!.\(@PQ7R=SNZ" *P15I9IM1AWRH"].[Y/^P)3^QO@SFV$D.<-!G%B4W:T MBC3:D6KFH!U.[YQ^YS1D"HEHR:T C@TKM 7RVQB#LCN]29HL*]^=N>(7<9:I M;R_1 A-*B(->.+UY.F4*"^0K\H0_(X42OF5>V$NTP(L2XJ 73A<>1P?J1,>S MY.5K!W+ %BA?Y L*[G2]\6R-*+T(I0Y EHX_.6 +!"_R!05WNJ+X;_8L%XJ<:2UTHH-M@@9TTI/^IX\=F MQ[YOEIK$EC.X1FL/T 75=IH%WX1S2OPKRE'IO#\#:X'6AVQ!J9UFOA>( M/8CP4?G;&\%]C,V-(;D[)FLD7[4J:($]]>, C7/[*.[^3:G1FU'E=:BB_XVB MV99>N"@IUP*;*NF#[CA^%97\G]02P,$% @ $!V6"1'$XW? M"P BX\ !4 !X8FEO+3(P,C0P,S(R7VQA8BYX;6S-G5UOVS@6AN\7V/_ M]>[%#%#'B;.S0#+M#-(T&1B3)MDZ;6>W6!2T3#M"9-*@Y,3Y]TM2'Y9('DE. M.R1[T;K2>ZB7XF.2DL6CU[]N5PEZ)#R-&7TS.#HX'"!"(S:/Z?+-X.-T>#8] MGTP&*,TPG>.$4?)F0-G@UU_^^A$5. MT6^$$HXSQG]&GW"RD5O899P0CL[9:IV0C(@=^8%/T4\'XS%&PV&/Y]EJW3T]'HZ>GI@+)'_,3X0WH0L56_ J<9SC9I5=KA]K#XDX>_3F+Z M<"K_FN&4('&^:'JZ3>,W WG,+T?CP\.CT1_OKZ;1/5GA84SE>8O( MH(R2I=CBCDY.3D9J;RDUE-L93\IC'(]*.U7)8F_/35-F[8A'.5+-W M'@:!"OF_82D;RDW#H_'P^.A@F\X'Y9H]KP5*:2Q)&!3; M[CE9V,TDG(]D_(B2)<[(7![H1![HZ%_R0'\O-E_A&4D&2"H%'V"]3AIE%4$C MUV9O"8_9_(*^S+4>[;KDS-&3?K+D=&5>8"IS-5\"8=+C%>BP.,CTAV/!5 MCHUD16AVGN TO5E,,Q8]G&WCM#R.JN2;00_]2*^ C#SC92TPCSI.1:$814P, M9.MLF.0G/0]?<+;J9:,X9ZR'^&LRJ\K/3[*P %2D(>,D91L>D;W:N%Z;OF>U M<+A*1(2#:Q4< [5*_0/50!:8XX>91%H+:;VJ2SD3R+M5IR%>S'+_(PYQS1+8;(@ MI3.2VJU6Y-AE89#2ZDTGHQ2C4OVM"'R_@>L.SW8S JA?+41>AJB&0>NXI!3> MJ6BUI0-1B= 7)?OFT>?[ 2%F9&0B/G9.86I"+V 81JUP5*KP -&MM4 BI4AI MOR\I*8D.ENQQ-"=Q#HGXL&-#_.?K.Q9M%,VB1*U"YFX7'$"F9.OK^[RW.6!( M;^E2@J3&<0.?B0//Y<$O$[RTV-?VNVIBJZVRC1L[@VADFR.]E2L-DB)?S?R. MI!&/U_+.9EL]&C+GC6XQ:;1]31,6 J8QF(2:UE/'_H$LXS3CZE9W->*T=&. MWG77WVI;'PNLXB"@Z>,0'"WJ0:B*\L31&:4;G'P@:\;;\&G*7%-C,ZG#4M<$ MQ8C%&(A&KD6YV!,1_]Y@GA&>/'="82A=/6"=+XSHH ?5N8>FPW60& M$ >$3KM#@" 1A)I1/D&:T(CQ-:L][G#.-J(#?#YG56BBU1H2 M$&!]? *8-4)?Y<^D(":7-*L"D"S!"W%G\[DX46GQSU5,R1%8?ZO6+5TM=IM, M680!D02[ _@IE*_*#TC&H!L:"C3C/:HZ]@_-N"\TXZ"A&;\$FKLG%@@TQWM4 M]=@_-,=]H3D.&IKC%T$C&MYK7W,N/M[P._9D>S@;5'I!QK1J!68G"P\7PUL7 M+#) SF=DB$],U,3JAM]R]AC3")XR0W(OP "FK=1HVO#0L1OLXJ>:$)=Q7ON: M?%+>^24I97YZF:9)>Q>3:\*#I&FLLW/)U3Z1N&5IAI/_QNO6"W&[V L>5L-6 M2!K*\%"QV>L")H]!(LC'A76!J_Q!P[J43-OO[-=FFZWJ)^;ZSB @L#DR$TOD M=T]RD>MFEHQR@H$>H;G;62-;3%5M7-L71A.;AHP65M]KH?'Q19:)[I+;>T;A M!P1,B:N6ALR5K:WO#Z+% 5-ZJRL94CI/=^-ELJW4WGW7]CD;V74[U4!>[@BB M=74WQC!=[G?W'QR6-LJY5-Y H(V&!)@ZD( @70EI')I1*B4ND8@EM. M)(1$-(1:!"AS+/*;Q<(ZVK>)74'1;;B$ U8& 4FG/2-9&"?#J!:!\A"D8OQB M,TG3#>%[P6,)\800:!X R="'B!-DLA.J/- G6U,2;<3X^'PTGMW%F9&$SBYQ M-B8!YJH12=L?!!N *9T%M4^F/ST:_S#[$951CIO_FMUQ+//H3Y]7,Y8 V:>L M*E<0M%@L.;!(@D !]J73<,U0(46YUD=VJH992W6T_:X L-HJF[ZQ,XA&MSDR MOOR-MO;4Y5]LHWMAB@ +$NPRUUV_S:3>_==J8B35KKG8S..,S',SES'%-(IQ4J5'M-T1[PYQ1DM/\Q4X'?HP M&.IGTL I#RMS&5:!NU27KF^EYP]@?"9)\CME3W1*<,HHF>?W4FR_%+7KW3XQ MTV&[^= ,( X"ISX.@4=G9-#P04:A,JRX$^:%I$\LV= ,<[66G-MZ)D#GEAS M9I,83100*79G "&5&.5J/PNT\^P1U20K?P4C6$%([GBY=JMI;=6V51L0,ZT& MH37<1X0P7WL#Z0G+7BRK;3.NK*6W:@!!J-0BN MGZQB9*H87#+E+64,/Q=3K25K>4I<4[E/'&-8-'/'5)* \+#Y:LD@PU&I]<+" M=(63Y.TFC2E)X8%(4[EEP6JQR4)#$A +-E\ "TJ*2JT7%BY6A"_%\/8;9T_9 M?9&?%:P;H';+1JOE)B-6:4"LM/D#F"E#4!Y3IM3U \]VEU \S[((U]0B=8P- M:%9CQM"%! QDSJ E(9&\WW+-,G3'T,>4H.R>H(OBC;SU3/!Y.;[>-!)%**H+[F2XZZ]$'0U-.DSI0*:UYWA*5Y#Y'AF;#&H M38QKBB 8 6U!T^+ZNP+\Y,[;S)(XNDP8AN^R-#2.,^:9]K1D>3M!0 28KJ 4 M>4J(E-)+^[_%](%OUEGT?,M91(A\RBJM>JNN^V\]H]TRLU>5FC3U"@V(LWW\ M @3NBD"U,E[51BR?-_-J;[97;[)/;S99*D=080R^"]X:Y/CGA1X5T'YD:(D( M"+T>-J$?'%0D4J&O4!Z,:M&>KL_2719 ,G_[_($L")?K#N[(-GLK#O30)OV8X)6++_P%02P,$% @ $!V6)XWY[,[" XV( !4 !X8FEO M+3(P,C0P,S(R7W!R92YX;6S5G5MSVC@4Q]]W9K^#EWTFW+J7ILUV$IITF%Z2 M#>EE]Z4C; &:"(F1Y 2^_4H&$\"6?-AN.=X^),0<2>?_.[*L8TONRU>+&8\> MJ-),BK-&YZ3=B*B(9<+$Y*SQ<=@\'_8'@T:D#1$)X5+0LX:0C5=__/A#9/^] M_*G9C*X8Y'Q]/A'P@CU+=ZY-8 MSF 5#@TQJ=[4UEZTU_]6Q5]R)NY/W8\1T32RO(0^76AVUG#MKIM][)U(-6EU MV^U.Z\O[=\-X2F>DR83C%M-&7LK54E:N\_SY\U;V;6Y:L%R,%,_;Z+5R=S8U MVV]9P'[+$\U.=>;>.QD3DX6]LIG(:^'^:N9F37>HV>DV>YV3A4X:.?R,H)*< MWM)QY'[;Z&U:7=A^8E@\8M*%K.6^;O6E[9+6UZS@5-'Q66-A#6S]W6?M7K?K M:O]YQ\@LY[9K:N9Z5B-J[;0\5U1383*Q[^R!G2)T86R'HDE>D6L?[IMAQIFO M.TPG:KK>EZ)S7MTQEK3^&0B'UH)999YM^<^ M.!*]C(+]XVO6T/E(&T5BD]?$R8CRK/ZOUF;/I/7-7HV)'F7=(-7-"2'SE6N4 M&YT?>?)Q?>"K.].H@W-'1BY,!4?7AOMV^]YN!_1<[7I.5)Q7;#_N1+/8>]<6 MK3E1MKYF/&5\TQ'&2LY\^-8-RJ#74B54V3&UW4;G;7L]'=B/&L!\RQ:9NX=K M&/Z6^^L =&L0@#XG6E^/AT;&]^<+!HE#LQ'V3Q9RP@6/4;">V_83 MY\,5)Y-RKGLF0+ =5+*ELK#0OJ8Z5FSN %40WK'$'I0/ UTB$FF$N*43YE(+ MY\I&0WC(\!3!'J8/&D2"LI%"<2Y$2O@MG4M5$8%=2R#X9[4 7R82B?>?*5&& M*KZ$("\8 ZG_4@OJ'JE8LQ([0=+,@8*0+UH#T?]:"_0^L4CLAU/*N;L+3@2H MWY?9 _G_5@O^?L$UB,#E@YL,6#7P(&P5 <;A]]K%H2 ;*10V%V8RL3(4( @% M8R#^Y[7 [Y&*"OY2)%#L&U-P0E4CZGLZD9A?,1T3OO+HRAXKNQ&\Y7J).90] M;C9;J1>5_U^4*##]+6,H>]P$MT+KDF[Z6K.B%10V;CKK4X<".;^9(8Q;51("O6\)A8V;Q894H@#O6X<5 MX0.1T,5;N@P1+YA"D>-FKT&=*,QO%)L1M1RRN'H\*=I"J>/FK&&E*-COR&*0 M6+?9F*V6;%73]Q:!!@$W807I1HG%0,12S>767>N^3.T9NNS+)#CL5Q2$Q@4W MDSV 4ITSI/$G#]NEENI%Y-_WWZ\5G?RT?/XW&L,98^;Y59HQ22?^7^M;I1\8*OU[E7X M"R6@,:A#\AM6C7H*K&8$D/Z?6T+!UR$1+E>)"?Q&:D/XWVQ>-1$MMX?"KT-* M'%)\[-N;JP[@[HOXUDKMF4!!XV;!I;J.S=:%6E'B[]"[%E"RN*EMF:HC@WTG MW4.9J13!V\)%*RA@W!S5I^[8@[/;6*:]H\+6U^!%>[A#[[Z>(_/\K)BQ'K@E M]:E8WP_R/,#SF$(YXR:609U'9CZ4G,7,,#%Y;SU7C/!RX&5V4-JX::1?X9%1 MWRCJ0D[M]#U;L>8VI:KK\=@W.H?LH>AQL\AJQ;@A&&B=4G5H($I*0<.!FU!" MU1]["*)Q:D?$9:<[NG.;K3T#4,$*"ATWF?2I.S+D#_).$??.A^%R-I+/FC*6ZD(:+RT4\)6)"_8LQRBVAI'%SR)!* MM/%Y AJ?)P>.S[BYI$\=$N35VGE[CEV/.)L0__Z\8 'P7J5:H ]H/O;VR&S; ME'MUD)IE?ES9#^7\/:90\LA;44,ZC\T\39BAR2]JD#U*,\=/E/.WPKY*(:4:"EHLDH90H\>O$6@X:C#<\\*W2BQ^"1Y:G&I M;#6L\IP5'E,H^SH\[_3HQ%F NEKKO;D^K=XC%T+O*P&-0!T>?(95(RW),]2] MEXL]T-?$D+6'H4#X2D #48>'H&'5:!L-5-\JF,CPD_\]0RCV.BP,+M6(0GLX M(YQ?I-JZK(/#SIXAE'8=5@"7:D2A?3FC:F+'NS=*/IKI>@]MB+JG )1^'=;Y M!C7C1&'QM)5_M:LP&((2:_ K(^K WZL6Z^TH<>S6A:PN^R(ARH,_9 \-0#TV ML/H5'SD$UV9*U?:L*W/&N1]:PU%="AH.W$08JA[G0KSU5H7@=7C'#@J^#BEO MF4*<#6CIB+/XBDL2G-_OF$%!UR&_+=&'POF"B'N5SDV\O%$RIM0]U]&;\P^0 M80$K@,:F#IGO04QP[D@\O6XT>[VHODY-]N9^ZU_POD2P'#1&=4B*(020YD[Z M:=<<32Z6MW1,E5ML<4<7YL(V=!^>2@&*0P-5CW="@7F4Q.MEJR#0-GEOOUU_ MXWZX_Y' 'OD'4$L#!!0 ( ! =EC]&5N971I M8U\X:RYH=&WM'6M7VLKV.[]B+O?V'EU+7@&DH.4NBFAI*WK GK;GBVM(!D@- M"N5B69V7O/GOV>A\?_FXXM7O2MF'7>8*U2K MU=P4VZ15H]HTMIV6SQ=RG\[?]_01&].,:7-!;9W-.UFF?9,,']_.F_9=RXPT MQ2'SNV] M<%YFBH4 SLKD1$>*K_N4SSENL"5V!SCA!?30BD%#EPT2P1[FX&W0T..9(:63 M>>,!Y7W9T'\1@0K/7,=B/+:U?!-I;@@W(V83QN-)@= M'/3**9#'_\IDR*G)+*-&>DP;UA]X+[>2LT;B$ M'S@ DLELV+E8OL917D='=QV,;G- I?R\TR-ZEZO7#$02R(=_C3&S#?@O3BTZ MO!Y0B[,'0,J'(+5LF(99$T"YU&K;!IN^8[/K/!C !MT,DT\L.JL1V[$9 MOC.G-114YH+TRP^F83 ;50$_0:N.-P8XNA+SJ>BBE6GPBP%*"&HPZ \QC5?I M4ZJ+/'Z![MDP:,#%S%I$$-)U*0G'N0CD[\%5"N.*%95T?2$K<8ASX3$C&6 H MF0NNFW'Y'LUQC4L_"^00Z3QK(VEKIZ!JF4!1LE-NI/W7:.%>I;DYGE@,;8&/ M)@)9H>*.Y_J8H)&<]IH_>#G0I<'[%BIHR>2 @X?SQZ:!+P8F1NA 8"O[\Q2=^Q/]@ M3A\9U1V1,W:%IUP@VS1\1%+L,MZWFAV[[JMWJD4;GA+0^-=\T M.FNV+SBZH^$CYR+2'PH'^)]EFEFCY_06+S^A;,VZ_U>:Z[R'J_C29=\M) MR)QM_?I..+A-X,FROT6D@?1M5ZW!J'5;G2O2;5U>=*]V84@@CN(>!%!$.-!1 MQVHB*12)XY)"><_8)\Z 7(U8"EYYKBE,0-B:0N!E#QEIZ )?%ZK%TM8IW0'[ M,?C"\739Q'$%V0L^,PJNEG%!V"VT3+GR-3/V:P38MVP$7B\9@4L9O;54:!=O M#6YN;JO&>/#V_$Q_D#50U=]7:7,J:@8&R]!V9-#9# AF=M1:%/)QUB)"7+I^ M3B&D3FG: 4$T:RW(;]/Q<\GNO1YK64Z+OIRJ:E:7#4V.2PH""XGQ8CHK\O?G MU:O3/PWCT4ZK4%BMI$5Q0W:G"LSDM>EPW92%K(-4V]:S/]BE[;6F, I)/EH% M=TXVH9SP"=,Q"3:(:1,PCV @W/W="96@?8O!*\L"/NBX&)@&A<' MDW%G&F*$3?,OCDC?<2&;R.B.9=$)!]D*?I-YVK%P _BWS(7YHU9 L7 F?BIW M+(R@D0^ZJ+UXH$#G$P2Z%1%HD!?'!3LM5\=D*:&IUG::CI$@W^Y14E9L$['K) D$)&NE\H9K5K6JH?: MAGR';^YC;,S#.;LGU0^#7T>,F$N^0,S+#5-%Q<=]-Z=P@/DWPTJ[OTY*'B@: MCR :*^DFQ_+I@D246,X,&+H@,"H;I.-D]V/G/"=]6WT[ M;O0(G9CCULC=R,0(^'DXU7)^K5E96 TM8C4:AN$RSOT?[TV;%>(MQB$MGU5/ MO+[PC.$RF%PZ,%#K;W.2'"K_V7@[O/W\M]9OWCQ>4EXF M,BQ" 81IA4J^\/.%"CZQ& Q,7)A81@OLK[PL[*]W M,"L#*/@#>.^ $%Z.''MMWO.FV?1>&U[KLO3ET:JE18I]RWC3]4KE9:92T?+/ MLL*WMZ@G_???+[5"Y8A#.XM-D /$EBPXP/#=\C"&2U&87."LU*CM5MH#[=E^ M3;_C"-*8X 8(- >_^'R>@AN&S$'5W5SIE>$C5=879G) U'($6%5TKRF+FI,\LYPX9 M 2]3R"[R,O..F!RD7##; ,X(!Y@S]BQ!;>9XW)H1#FD7'\PDO(%I@280IP\8 M53;F2%CA&J<'<(#K]BQX-X!$Q;G#?A@2F9A]/:KSVG24S*P#ZZIH"YPDS>L_VI>D^.5@5 _5] 0F8 MI$"M2D*A1#,%+20,D57GN2B4\EG5\AE*0]67ADN7H0+B2ICE:UC3^O!FP;4A$IJB?3]ECI (@9/00R%;49)$92C(RVU]_?3%94VW^. MM+0Y]YA[K\Q4WG"]VGGKV.=;<2JE-3*S0N'N)*?(,J4]?3/)\=O^$I*3$Y?6@!^U]; M%&+X I#$P0D:\4L2P>)@Y85,YJ[P?*#:AZ2/B(Z[X1/KTSX;YO@*.-WS94O7S]G!:TO!2+6C%_[AR>@>=+IB6O_Q$@FL]GYF^MOE^=G;-@ZZWV^ M9[/J$YUXBCJ.R%+0,@\@)Y8PB01Z0/XCX9()=[G,K(T%&& .M+STTQ284GG@J @<6_< M5N;J_%-J0'YS4[F:GFY"PUCW$J75HG3R3"/TG7<,8S3TJ'%]I M3Z?YT9K])$\_#9M:O&)^,XOW$&NW@U7;G98CVK:!B38C_1G1Y4H%]+J!B)K) MC731U824R0G('8@+ AZ2H>OXPD Y,=C M-5N:E48SI>#A8>EJK Z M@%*<)^LXV,J1K!'GR_NX8J1R?:V?T59!I.(.LRS#PO0?N^]GM\)#UQR.0,!; M"=Q8UM&7D4T;0:\SV:FI^L37>&Y/"J4O[%LCSQZV@7^S&D\Q9FM_+''WE7=^ MA0++/;HP6"/=N/:\I"HIJ2KFRIH;V"S"+*8+4 3;D448#[PSM@*T_LH>W@-E MRL*,.BB.TR5Q63-$?F<":A0C&T8$;UQV:W+H!^I%;=VD%J&ZO/8(U\+Q$BZ# MN@97:WI&4@6HN$?W UT**U"6S*?V5Y_#G91PGQ0ZB!7#_EHE6RRKS8P2?.BJ MH$LZ9$< XZN'-5) )2_\D7%"Z/*>< WQ,*:&>"B!+VIQX=K;G U M$[*^XQR1BXDL1M?(&WD;$$Y &$@N@")?)%!3?!'K0)8WGP9QA7_\?WF:^RZC M-YD^ WL!]$VD:&PV]9.HI$@Q#&M,&&%X;,@#*7%;E_GO!?_+UYU]T-7#R31. M:^[;*-J&4)YHV;R6O6\?ZL-A=QGW+"'W35Y,F.LOSH#C 3D)?%+3 1^)+U;P M;RUH#D1)[A/9C?V_L(D\I"@#S[5-/F)& MBN*I]Y'9-P6I5K,%#(;$"%HT/=<%VH,CXQ ;S;=?(1,A\V$0Y"W."JF,1G:= MJQB&@?,[V[)XV![:S&_VC+1/8?O0YL4H450("O&D0BN< RQ]PQ Q5,XB8W)G!P$ $# M/O^(KAY%S#W0/X7YUQ=K=3/)QT;W)//^XN)=NW.F;N0Y;W6NMGX MAE%M'\D5ZEV@T&&U6[$6!S*!IJ;-4R!O=Y!"92S'N<&V/*B+<>A&!;EC_K9, M-"(@K=SK?P%]4R8%/M(!@\3/[:-.+C96^GIXZ9JW:(=#FO$>?OB[-KL8RXU1 M5U)25ZKE+&F 3H1(\,D,V:$-Q^?X91SIV^?@ W $(Z+ 0D94!V>C>D,T0 / MA2?8.GY@;BK)8&3,J"WWH/J;2YDAMX3RQ3@M>L>E=03;'!X0$ 10PD5C;<#PW!8\]69<0YJV<^P,L M;4B/"% J3Y"%OH2Z,YC&T!NF+B!:+ZM$%S P'7&:M/T')PD*.BTF"JI$DO\ M22WX$\A>PIA\[<'J#+A1\'E<=\U^H&T"_$SY<$*AGSS:H#:ZI%D<%29[/DF]5C,())=M MP#(R""AA9OP;<.;13B&/UD-5G\"]?O7D[1?6;$Y;J.&?!W-)6GX;!$U*C W_ MBIK5D;6:68B(\0" S! .UED8M$74XM+04@/OS6= %P4AT?TH9.AO/A_+LJ2EV+O]HGF4(5E$#(Y!QQ(B7.Q+%,F?.I*XB6^G4]F% L$=NW M%&<6C?^'&Q=U65(-Q X M0A$\=PT#$AG6Y2+ ^3^8HA*168'LGX(>8@\R :V MT/"@MP&X+6>"C#V8/Z2W(*^T#_$3=@O,-F*5LP"B,O2L4(IG8753/3@(RIW8 MP'%G"%-'YF(XBM7* >8>,/$O$.!\,NGBOE@$CR<,Q!VF'G%5>5GY=2#LH+! M0.VV!4R/*I3ZE,S])EB4L8.^1PJ>+P$J$%\C6H_UI"F(0V%J'=N2"QV^P\/A M*?\?K8N%=!HK_S!I+-9LO;*'&LJBD]!;RI!R!3!A!O'=>6"DM50F?I$R' M-]0%8]I.^E8*>/H,)':I#-]?+L/[J"LOUNXY7R-W03VBX]PKU,$P'[3;,XGB MZO)%.IN3?"(C-5F5_][#Y/<@PR+-IILVZL>4^-?_JXK@-9M6JV K1F)\WZ N MI;_I^G4L0X:VT3HC!FOHO*2'7=[70K&7XQ,@)%51=O[.'G#$,/WKU MHZ^V_!L^!/^(SSS(W<]NUQ)OI_JTLOCR7-9E=[CVNV9Q5HM=G+UO)75[B[?/ M?G$6^:W]O(NQ/]7"ZP]1F5W4?'=9P][V%?GMLT[CZD-WBQ?R[W#^XU=5PK=7 MJW*"3&-513-Y\8I$%J]BMET9'J3GLB1IJ.3>KWGY-7L@3)5%(>V !R-J#3!Q M1D R(_<;8"'5LX63DN"H)T:."_;1V,X^PK6,>A[[&E"N-F]D?^G5J=U MU6Z2U^V+7K/=ZC1;O0/2[C23]QQL&H'&Q9+?<37<(V+3UQ!O;WP71X[GR%N* M4WM)76XY=TDG;)_K]R_-DT]%_)N-/>72GI^@_L-[C>XW^!^@WLDN%\] =FD9E,,;?!^ MC_?0?4<)YW?%9J.*37&7%9N$HDH._V2R_&/<8FS5_P]02P,$% @ $!V M6"-5 M_T,O-UP2R8))+4.EPDS0!CP9#)/6VVI;7>0U$JWA/'^^OW.:4F6P3@D M,Y L.WF(0>[N<__.I<7VV][1X>MF8_OM7G<7GX+^;?<.>H=[K[>?^$]\^Z3X M>OO-N]T_Q%GOC\.]5TL#DV0OQ=IJFHF>CI43QVHL3DTLDY9_T!)GRNK!$C9B MZTFY+Y9VJ).78G7I]?:;UWN7(]W7F7CQHK.V_>0-J)[]EXM+7T=E=L*O"6JP[!T=4MDZC)KRT@/ M\2A02:8L.-A_=]RKG]QV^C\*QZ^G&2OF@TI4I@/Q1AL7:)4$.+_9.$B"CCA5 MJ;&9$_MY%(D_E+1B?75]0^SK1":!EA$6N#S" J]0HE1(_*V$*55ZA9TY#*W] M-0P=O-[!>3K)52AD> &]J!C?"3,0N\?2J78?_X7")(&)S'#2;*36#*V,16;& MTH9.G(RP0, E#^Z!UR#2B0Y@.)?EX40,C!792(G,*IF5;*>0@7Z'2P32!CH! M.2$3R("E5D0&^Z/)_?!;:!2TK8A5)EW&?#D3Z5!D>6RL6\C(7^1U!Y5?S:-U M?4MY:CLS*9^\);Z4H7;?9)F)>?<"OU_C;P]>[R6A"IL-,N:$XG2LLY'XX45G M5<0ZBK1)R+*!="/XG1CD9,U462C3)(4&%T?++?B^E1J^7+A2\W^:OP6&_IB[ M3 \FC"#[I]VC@^.?WG:/6N*H*QXG(;2V)9:/$ LCL;[>(@S<7"&(:3;*;^=A MJ& (73[NGNUV?WTI/KPY>+:+:)0)!\&"4 MT(\:VI)A:)5SM 6GA^0=# ;P%0AA(45F0CD1EC,!N9@&W ^J!&"+!% B"3N? M(F<4NPI0V =B;*RQSC8Z=VV].\VG=1\Y5>3@XJT>CO#E*'/S"XH[E:[7?7.X M)W;V#@]/NKN[\-A72ZM+_/O927>G_/TK.5D8L5M ES ;T7FKCZ"/WFE)YD)9 M]LV2=YQ"1=EV;W<>5A:25<>M>S1XTMM]7=M1^_(F@US#CX$$ZDU>BK-)W#<1 M5!?K,#39%$5F2@J) MGI6)&RC;;$R7,!Q3?/R6("2MT]F$ /F])MUJ"5A I&=;O[WO^A]6*!"+Y,?[ M0G6A(I.6.9H><7DABG*BPS)1!=T[)?G(.?[VD_OPDY^ Y$BD\)2A-6/RC+X) MV;I( R:W92G22&98M< 5_J=AUP?&[PIYKZRWH:U8GBL4LTI"Y1P*2&;" M7%#TD6+) @2&(,;%XY4J\18H9])#<(0]8\_J#R5TF@V0@),938:(_/!#I3P M.^+W,H87VG4\99".=4HU&QS]V++8;BW:2]Q!)CHZ,9D:(^F.)A#0ZA *]#T# M'S7/2<"C$GT5:8"%%Z(B.J72;%#A8#7G_!C)6Z=1O0.(D>\C*(;,@]:$)4[! M"F2"C!!I6#@\-L-C$Z4HV5-K(%.J*,A1;]="H*SY?'G?XGV%9M1EH#-OKSS! M*>?,W2!G:Y8LPM@DMG1.9:[EW8:*)9(.>W]6@X%5$[&GG4I0G@RAD9V15@.Q M=ZF"G$NF=X.!1O5#1Q6%VL.I7<[R&"L9H*[W\62\?>W(FZG=;S8H;+Y!<7-' M5(Y5!N=SMRM7$;=P?X;F2QW#X:.)^&&SLU9V5)UI34 N6L_0ZC)5B5.WHX.= M%"R$"7U06.MLE!1:%!?KSSH_/H*/PN=_V.@\K?JY@34Q\?.\>J(3'ZQ68QM3 M1(NG3=@1O9%V%1E!8F$1%(;D)T(/5$C=$#0@^+2?$:O9@.^ SQG*D&2=8L[ MGRC,*LR+$$D)@\ULW5+@$:MH/-(!8ZOUW"4 3HW#26F>9D%B THW$QFA?$KE MA)ARS,T5*ZW7]#2F0X'2"H$=>JT16R[O>\Z49[6'1!)*FL;4>BPG=DQ''&9A MJ=M%=H2-T"61\@C^A]!>G2VQ^;SS_!'.*8Q .8J/=#)6A:%*/7:$+RHBG[#" M& D&*<"W<[?QK6:C?UXG"Z1Y&#A')BF&"(469@=#,S9O-N;-B>Y< M$U>&M7=.K-LW>39O4'-/].]/V)N'4<@"SVWTO*Y"*6I):RZ,-$%SP *(:H>@_-_ MJ6BH-KC(3J)S#,X'H\[E]Z$ MB(D.O,P_)W4BS20J0 .5^&H$PX2;DO\HWUX4M^8\P>BUGMJ1,KS M_]%NH^-04?A2G,BAVL(AGW+"+- 2[79Q5;R]>_!^]@+53YZ>S9D\\;.^L:&R MU;,WD42S2-=2' @TC/J2L5AQ&E O E2 M?*GF1&7O^0I+R_\D&KAS&M6-Y$: M\(ZK$ZV-C4=3J\R=>6UL/KKAXJJFW5*O6Z(W2<%@U\J^#K;$,>I/K_MC0PI? MJV]Z4NZB;VZBOG&%NJ61^"S+]5'4]A,8 M]VGV)G7"W1&K(?)J:#9-H1W2B:X:%@ M5!6MY35!_*0,G":BM@O'86EF+ \XL9Z%7:;F3R M*)Q=ZGW@RGX%9<;U8Z>S2R\IM%8.* I%UNI0U)WH-%"(B@AK_+RR-6-\BZ[5 MTM*7 D6;F/>-\.KS-_1<^LT.D.?-CZ>5\%Q:S08=,1V?W^)U%7'#VRKB:U\D M06%]=0Q\FY*UQ=*S60=5^-YBDB\K,TW'^3S4W&PM'N,3EU\]A[_.;66[9F-J MKF\WAX^?N"&?R&1]X")A1V>OWM@*U-3-]O2 M\1#QZUHZ4>OHX!!_14LGNMR^WP3]M71#0U9(2\%3QGJS4;2O,Z#3JJ[+:JE1 MBB3GJ2=L!=\]=[PH)\W1^>2N'7'$LP0D)W!&5W 1^BF9$V:13P193I--TH1W M;ZA 66[A< RH!B,"[\+VD+E\QP3D0ST8@'A;'GA/RB'((W&^ Z)UG]Y-0WONAL4/3X2D:6 M;S"X+;&\_I64R#KS;P&F:(CC-U9J?C0IUU7TIN\KMJI!EA1Y"_A;R8J M:C0W5YJ-@=11;GE.C3",T+UY?ZHYS@RP30^"S"SLS<,L!E.3\HA?M( C< MI]IV;;7]2ZNXM@ 6?KRZSI)K;+;GN_<'N^VU%Y1!N7OVD#U4)C54.E U S!* MLBO[3G.D-TG7=A?2^9E_L_';N:4$48! ,@#MK'2<(QV&*$[VD'I:9+NID!X' M)[Z801;F](8\&.;87;L[;%4/Y06\M B,5M5W<%'"AJ""%4G;@UYQQ:-=5(SW MB)MB@;%:A#QE&.+/P6E%EM%O.\7CW0P_HT^-4.*$N! M#Y\J2\N"E:K'FX'AT@LJ%_U\%I[?]+D41D1QEI#35%[TNE)?*T72\X' M23B#+J%1/@ +82FYV138!"\J>A/J71+^=0%L="B %+HOB7Q]RG7U@< VL(' M=S=$K_##A"\?SIL./_=V1$])=!F'ASMW3@S8!^3HC7" NVMBR\\W4"EL_OBT M_7Q]\\>[IG;9U^9?'[- 6[H?N$_?^(Y>P?\_^.. [YV_[P=9OI_[H?4M\2[E MY/Q2'*(T^?NZZ!M<%ZW?ZW71?5_>7''V)_1GJ?[O5/V?L_X74$L! A0#% M @ $!V6"C5;?C% P KPX !$ ( ! 'AB:6\M,C R M-# S,C(N>'-D4$L! A0#% @ $!V6#@(3R+U" 26@ !4 M ( !] , 'AB:6\M,C R-# S,C)?9&5F+GAM;%!+ 0(4 Q0 ( ! M=E@D1Q.-WPL (N/ 5 " 1P- !X8FEO+3(P,C0P,S(R M7VQA8BYX;6Q02P$"% ,4 " 0'98GC?GLSL( #C8@ %0 M @ $N&0 >&)I;RTR,#(T,#,R,E]P&UL4$L! A0#% @ $!V M6/UR'U(1%@ I7\ X ( !G"$ 'AE;F5T:6-?.&LN:'1M M4$L! A0#% @ $!V6"- XML 19 xenetic_8k_htm.xml IDEA: XBRL DOCUMENT 0001534525 2024-03-22 2024-03-22 0001534525 XBIO:CommonStock0.001ParValuePerShareMember 2024-03-22 2024-03-22 0001534525 XBIO:PurchaseWarrantsMember 2024-03-22 2024-03-22 iso4217:USD shares iso4217:USD shares false 0001534525 8-K 2024-03-22 Xenetic Biosciences, Inc. NV 001-37937 45-2952962 945 Concord Street Framingham MA 01701 (781) 778-7720 false false false false Common Stock, $0.001 par value per share XBIO NASDAQ Purchase Warrants XBIOW NASDAQ false